Definium Therapeutics, Inc. is trading 5.1% down at $23.34 after a hotter-than-expected U.S. jobs report pushed interest rate expectations higher and pressured growth stocks broadly.
- The decline follows a multi-day run-up in the shares, with investors locking in recent gains as the Nasdaq and other risk assets sell off.
- Renewed concerns about a prolonged restrictive Federal Reserve policy are weighing on the market following the strong labor data.